Please assess the completion status of the following clinical trial:

Trial Title: AMA1-C1/Alhydrogel + CpG 7909 for Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 45 years, inclusive.~* Good general health as a result of review of medical history and/or clinical tests.~* Available for the duration of the trial (34 weeks).~* Willingness to participate in the study as evidenced by signing the informed consent document.~Exclusion Criteria:~* Pregnancy as determined by a positive urine Beta-hCG (if female) at any point during the study.~* Participant unwilling to use highly effective contraception methods (such as: abstinence, birth control pills or birth control patches or vaginal ring, diaphragm with spermicide, IUD (intrauterine device), condom with spermicide, progestin implant or injection, surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or a partner who has had a vasectomy) for the duration of the trial (if female).~* Currently lactating and breast-feeding (if female).~* Evidence of clinically significant immunosuppressive, neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.~* Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the volunteer to understand and cooperate with the study protocol.~* Laboratory evidence of liver disease (aspartate aminotransferase greater than 1.25 times the upper limit of normal of the testing laboratory).~* Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory).~* Laboratory evidence of hematologic disease (absolute neutrophil count \<1,500/cubic mm; hemoglobin \< 0.9 times the lower limit of normal of the testing laboratory, by sex; or platelet count \<140,000/cubic mm).~* Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.~* Participation in another investigational vaccine or drug trial within 30 days of starting this study, or while this study is ongoing.~* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.~* History of a severe allergic reaction or anaphylaxis.~* Severe asthma (emergency room visit or hospitalization within the last 6 months).~* Serologic evidence of infection with HIV-1, HBV, or HCV.~* Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study or while the study is ongoing.~* Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to entry into the study.~* History of surgical splenectomy.~* Receipt of blood products within the past 6 months.~* Previous receipt of an investigational malaria vaccine.~* Receipt of antimalarial prophylaxis during the past 12 months.~* Prior malaria infection.~* Travel to a malaria-endemic country during the past 12 months or planned travel to a malaria-endemic country during the course of the study.~* History of a known allergy to nickel.~* Pre-existing autoimmune or antibody mediated diseases including but not limited to: systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia; or laboratory evidence of possible autoimmune disease determined by a positive anti-dsDNA titer, positive rheumatoid factor, proteinuria and/or a positive ANA.~* Chloroquine and related compounds within 12 weeks of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- B (Type: EXPERIMENTAL): 80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum and 500 mg CPG 7909.
- C (Type: EXPERIMENTAL): 80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum alone.
- A (Type: EXPERIMENTAL): 20 mcg AMA1-C1/Alhydrogel® with 377 mcg Aluminum and 500 mg CPG 7909.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete